Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 17-Apr-24 8:21 PM View:  | Syntone Ventures LLC 10% Owner | Outlook Therapeutics, Inc. (OTLK) | 15-Apr-24 | Purchase | 714,286 | -- | -- | 72% 991.15K to 1.71M | |
| 29-Mar-24 10:39 AM View: | Haddadin Yezan Munther Director | Outlook Therapeutics, Inc. (OTLK) | 28-Mar-24 | Purchase | 1,882 | $11.82 | $22,241.80 | 59% 3.17K to 5.05K | |
| 20-Mar-24 5:20 PM View: | Sukhtian Ghiath M. Director 10% Owner | Outlook Therapeutics, Inc. (OTLK) | 18-Mar-24 | Grant | 2,305,710 | -- | -- | 66% 3.5M to 5.81M | |
| 11-Mar-24 4:43 PM View: | Evanson Jeff Chief Commercial Officer | Outlook Therapeutics, Inc. (OTLK) | 07-Mar-24 | Private Purchase | 62,484 | $0.42 | $26,243.30 | 8% 745.98K to 808.46K | |
| 21-Apr-23 9:05 PM View: | Dagnon Terry Chief Operations Officer | Outlook Therapeutics, Inc. (OTLK) | 20-Apr-23 | Sale | 520,000 | $1.13 | $590,200.00 | (44%) 1.17M to 653.06K | |
| 24-Jan-23 8:08 PM View: | Evanson Jeff Chief Commercial Officer | Outlook Therapeutics, Inc. (OTLK) | 20-Jan-23 | Sale | 267,000 | $1.11 | $296,370.00 | (26%) 1.01M to 745.98K | |
| 19-Jan-23 8:05 PM View: | Evanson Jeff Chief Commercial Officer | Outlook Therapeutics, Inc. (OTLK) | 19-Jan-23 | Sale | 103,255 | $1.22 | $125,971.00 | (9%) 1.12M to 1.01M | |
| 19-Jan-23 8:05 PM View: | Evanson Jeff Chief Commercial Officer | Outlook Therapeutics, Inc. (OTLK) | 18-Jan-23 | Sale | 33,738 | $1.25 | $42,172.50 | (3%) 1.15M to 1.12M | |
| 19-Jan-23 8:05 PM View: | Evanson Jeff Chief Commercial Officer | Outlook Therapeutics, Inc. (OTLK) | 17-Jan-23 | Sale | 27,162 | $1.31 | $35,582.20 | (2%) 1.18M to 1.15M | |
| 29-Dec-22 5:01 PM View: | Sukhtian Ghiath M. Director 10% Owner | Outlook Therapeutics, Inc. (OTLK) | 28-Dec-22 | Grant | 14,230,400 | $0.88 | $12,500,000.00 | 25% 55.82M to 70.05M | |
| 11-Oct-22 5:09 PM View: | Sukhtian Faisal Ghiath Director | Outlook Therapeutics, Inc. (OTLK) | 07-Oct-22 | Private Purchase | 30,000 | $1.29 | $38,700.00 | 79% 38.0K to 68.0K | |
| 11-Oct-22 5:05 PM View: | Haddadin Yezan Munther Director | Outlook Therapeutics, Inc. (OTLK) | 07-Oct-22 | Purchase | 3,600 | $1.27 | $4,572.00 | 6% 59.74K to 63.34K | |
| 11-Oct-22 5:05 PM View: | Haddadin Yezan Munther Director | Outlook Therapeutics, Inc. (OTLK) | 06-Oct-22 | Private Purchase | 29,743 | $1.29 | $38,368.50 | 99% 30.0K to 59.74K | |
| 05-Oct-22 4:43 PM View: | Hilzinger Kurt J Director | Outlook Therapeutics, Inc. (OTLK) | 05-Oct-22 | Purchase | 15,662 | $1.23 | $19,264.30 | 3% 457.45K to 473.12K | |
| 05-Oct-22 4:43 PM View: | Hilzinger Kurt J Director | Outlook Therapeutics, Inc. (OTLK) | 04-Oct-22 | Private Purchase | 95,541 | $1.29 | $123,248.00 | 26% 361.91K to 457.45K | |
| 03-Oct-22 5:19 PM View: | Hilzinger Kurt J Director | Outlook Therapeutics, Inc. (OTLK) | 03-Oct-22 | Purchase | 41,798 | $1.25 | $52,247.50 | 13% 320.12K to 361.91K | |
| 03-Oct-22 5:19 PM View: | Hilzinger Kurt J Director | Outlook Therapeutics, Inc. (OTLK) | 30-Sep-22 | Purchase | 33,199 | $1.26 | $41,830.70 | 12% 286.92K to 320.12K | |
| 03-Oct-22 5:19 PM View: | Hilzinger Kurt J Director | Outlook Therapeutics, Inc. (OTLK) | 29-Sep-22 | Private Purchase | 13,800 | $1.19 | $16,422.00 | 5% 273.12K to 286.92K | |
| 23-Jun-22 5:07 PM View: | Trenary C Russell III CEO and President Director | Outlook Therapeutics, Inc. (OTLK) | 21-Jun-22 | Private Purchase | 19,925 | $1.06 | $21,120.50 | 57% 35.0K to 54.92K | |
| 23-Jun-22 5:08 PM View: | Dagnon Terry Chief Operating Officer | Outlook Therapeutics, Inc. (OTLK) | 21-Jun-22 | Private Purchase | 10,000 | $1.05 | $10,500.00 | < 1% 1.16M to 1.17M | |
| 22-Apr-22 4:38 PM View: | Sukhtian Faisal Ghiath Director 10% Owner | Outlook Therapeutics, Inc. (OTLK) | 21-Apr-22 | Acquisition (other) Duplicate | 27,982,500 | -- | -- | 101% 27.83M to 55.82M | |
| 22-Apr-22 4:33 PM View: | Gms Tenshi Holdings Pte. Ltd 10% Owner | Outlook Therapeutics, Inc. (OTLK) | 21-Apr-22 | Disposition (other) | 27,982,500 | -- | -- | (55%) 50.97M to 22.98M | |
| 03-Mar-22 5:30 PM View: | Hilzinger Kurt J Director | Outlook Therapeutics, Inc. (OTLK) | 01-Mar-22 | Private Purchase | 27,708 | $1.69 | $46,826.50 | 11% 245.41K to 273.12K | |
| 28-Feb-22 5:57 PM View: | Hilzinger Kurt J Director | Outlook Therapeutics, Inc. (OTLK) | 28-Feb-22 | Purchase | 6,000 | $1.60 | $9,600.00 | 3% 239.41K to 245.41K | |
| 28-Feb-22 5:57 PM View: | Hilzinger Kurt J Director | Outlook Therapeutics, Inc. (OTLK) | 24-Feb-22 | Private Purchase | 41,160 | $1.46 | $60,093.60 | 21% 198.25K to 239.41K | |
| 23-Feb-22 5:42 PM View: | Hilzinger Kurt J Director | Outlook Therapeutics, Inc. (OTLK) | 23-Feb-22 | Purchase | 79,535 | $1.44 | $114,530.00 | 67% 118.71K to 198.25K | |
| 23-Feb-22 5:42 PM View: | Hilzinger Kurt J Director | Outlook Therapeutics, Inc. (OTLK) | 22-Feb-22 | Private Purchase | 95,597 | $1.49 | $142,440.00 | 414% 23.12K to 118.71K | |
| 01-Feb-22 5:09 PM View: | Pillai Arun Kumar Director 10% Owner | Outlook Therapeutics, Inc. (OTLK) | 01-Feb-22 | Disposition (other) Duplicate | 2,500,000 | $1.25 | $3,125,000.00 | (10%) 25.48M to 22.98M | |
| 01-Feb-22 5:05 PM View: | Sukhtian Ghiath M. Director 10% Owner | Outlook Therapeutics, Inc. (OTLK) | 01-Feb-22 | Acquisition (other) | 2,500,000 | $1.25 | $3,125,000.00 | 5% 53.32M to 55.82M | |
| 06-Dec-21 5:26 PM View: | Dagnon Terry Chief Operating Officer | Outlook Therapeutics, Inc. (OTLK) | 06-Dec-21 | Private Purchase | 25,201 | $1.38 | $34,777.40 | 2% 1.14M to 1.16M | |
| 06-Dec-21 5:27 PM View: | Trenary C Russell III CEO and President Director | Outlook Therapeutics, Inc. (OTLK) | 06-Dec-21 | Private Purchase | 25,000 | $1.39 | $34,750.00 | 250% 10.0K to 35.0K | |
| 03-Dec-21 4:32 PM View: | Dagnon Terry Chief Operating Officer | Outlook Therapeutics, Inc. (OTLK) | 03-Dec-21 | Private Purchase | 10,000 | $1.42 | $14,200.00 | < 1% 1.13M to 1.14M | |
| 06-Dec-21 5:25 PM View: | Evanson Jeff Chief Commercial Officer | Outlook Therapeutics, Inc. (OTLK) | 03-Dec-21 | Private Purchase | 35,200 | $1.34 | $47,168.00 | 3% 1.14M to 1.18M | |
| 02-Dec-21 5:08 PM View: | Sukhtian Faisal Ghiath Director | Outlook Therapeutics, Inc. (OTLK) | 02-Dec-21 | Private Purchase | 18,000 | $1.40 | $25,200.00 | 90% 20.0K to 38.0K | |
| 02-Dec-21 5:09 PM View: | Haddadin Yezan Munther Director | Outlook Therapeutics, Inc. (OTLK) | 02-Dec-21 | Private Purchase | 10,000 | $1.39 | $13,900.00 | 50% 20.0K to 30.0K | |
| 02-Dec-21 5:07 PM View: | Trenary C Russell III CEO and President Director | Outlook Therapeutics, Inc. (OTLK) | 02-Dec-21 | Private Purchase | 10,000 | $1.40 | $14,000.00 | 100% 0 to 10.0K | |
| 01-Dec-21 7:32 PM View: | Sukhtian Ghiath M. Director 10% Owner | Outlook Therapeutics, Inc. (OTLK) | 29-Nov-21 | Private Purchase | 16,000,000 | $1.25 | $20,000,000.00 | 25% 62.8M to 78.8M | |
| 20-Apr-21 7:54 PM View: | Kenyon Lawrence A CEO, Pres, CFO, Treas & Secy Director | Outlook Therapeutics, Inc. (OTLK) | 20-Apr-21 | Market Purchase | 10,000 | $1.83 | $18,300.00 | 112% 8.93K to 18.93K | 0% |
| 20-Apr-21 7:55 PM View: | Sukhtian Faisal Ghiath Director | Outlook Therapeutics, Inc. (OTLK) | 19-Apr-21 | Market Purchase | 10,000 | $1.82 | $18,200.00 | 100% 10.0K to 20.0K | (2%) |
| 20-Apr-21 7:56 PM View: | Haddadin Yezan Munther Director | Outlook Therapeutics, Inc. (OTLK) | 19-Apr-21 | Market Purchase | 10,000 | $1.82 | $18,200.00 | 100% 10.0K to 20.0K | (2%) |
| 25-Feb-21 8:52 PM View: | Evanson Jeff Chief Commercial Officer | Outlook Therapeutics, Inc. (OTLK) | 23-Feb-21 | Market Sale | 8,554 | $2.09 | $17,860.80 | (< 1%) 1.15M to 1.14M | (10%) |
| 25-Feb-21 8:51 PM View: | Dagnon Terry Chief Operating Officer | Outlook Therapeutics, Inc. (OTLK) | 23-Feb-21 | Market Sale | 15,900 | $2.09 | $33,199.20 | (1%) 1.14M to 1.13M | (10%) |
| 17-Feb-21 9:13 PM View: | Dagnon Terry Chief Operating Officer | Outlook Therapeutics, Inc. (OTLK) | 12-Feb-21 | Market Sale | 63,700 | $2.55 | $162,435.00 | (5%) 1.21M to 1.14M | (8%) |
| 17-Feb-21 9:14 PM View: | Evanson Jeff Chief Commercial Officer | Outlook Therapeutics, Inc. (OTLK) | 12-Feb-21 | Market Sale | 56,973 | $2.55 | $145,281.00 | (5%) 1.21M to 1.15M | (8%) |
| 11-Feb-21 5:46 PM View: | Sukhtian Ghiath M. Director 10% Owner | Outlook Therapeutics, Inc. (OTLK) | 10-Feb-21 | Grant | 1,013,630 | $1.00 | $1,013,630.00 | 2% 61.79M to 62.8M | |
| 04-Feb-21 8:54 PM View: | Syntone Ventures LLC 10% Owner | Outlook Therapeutics, Inc. (OTLK) | 03-Feb-21 | Private Purchase | 3,000,000 | $1.00 | $3,000,000.00 | 18% 16.82M to 19.82M | |
| 02-Feb-21 5:32 PM View: | Sukhtian Ghiath M. Director 10% Owner | Outlook Therapeutics, Inc. (OTLK) | 02-Feb-21 | Private Purchase | 8,360,000 | $1.00 | $8,360,000.00 | 35% 24.07M to 32.43M | 13% |
| 22-Sep-20 5:14 PM View: | Haddadin Yezan Munther Director | Outlook Therapeutics, Inc. (OTLK) | 22-Sep-20 | Market Purchase | 10,000 | $0.72 | $7,245.00 | 100% 0 to 10.0K | 120% |
| 17-Sep-20 7:18 PM View: | Sukhtian Faisal Ghiath Director | Outlook Therapeutics, Inc. (OTLK) | 17-Sep-20 | Market Purchase | 10,000 | $0.67 | $6,731.00 | 100% 0 to 10.0K | 136% |
| 15-Sep-20 6:31 PM View: | Thurman Randy H Director | Outlook Therapeutics, Inc. (OTLK) | 14-Sep-20 | Market Purchase | 10,000 | $0.62 | $6,200.00 | 533% 1.88K to 11.88K | 157% |
